Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma
| Autor: | Susan K. Gibbons, John H. Malfetano, Robert A. Ambros, Henry M. Keys, Mary J. Cunningham |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Brachytherapy Urology Uterine Cervical Neoplasms Antineoplastic Agents medicine Carcinoma Humans Cervix Aged Neoplasm Staging Cisplatin business.industry Extended-Field Radiation Therapy Obstetrics and Gynecology Middle Aged medicine.disease Combined Modality Therapy Surgery Radiation therapy Survival Rate medicine.anatomical_structure Oncology Epidermoid carcinoma Concomitant Carcinoma Squamous Cell Female business medicine.drug |
| Zdroj: | Gynecologic oncology. 67(2) |
| ISSN: | 0090-8258 |
| Popis: | Objective. The aim of this study was to investigate local regional control, survival, and morbidity in patients with FIGO IIB and IIIB squamous cell carcinoma of the cervix treated with primary extended field (prophylactic paraaoratic radiation) radiation and weekly cisplatin. Methods. Sixty-seven patients (44 IIB and 23 IIIB) with carcinoma of the cervix received cisplatin at 1 mg/kg (up to 60 mg) weekly and extended field radiation therapy including the paraaortic nodes and brachytherapy. Results. After the scheduled therapy 94.1% of the patients were complete responders. Seventy-five percent are alive without evidence of disease with a mean follow-up of 47.5 months. Conclusion. This study confirms the ability to give concomitant weekly cisplatin and prophylactic paraaortic radiation with minimal morbidity. The encouraging Kaplan–Meier survival of 75% and only eight pelvic failures warrants further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect